Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABEO - US00289Y2063 - Common Stock

5.41 USD
+0.11 (+2.08%)
Last: 12/24/2025, 8:12:06 PM
5.41 USD
0 (0%)
After Hours: 12/24/2025, 8:12:06 PM
Fundamental Rating

2

ABEO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. ABEO has a bad profitability rating. Also its financial health evaluation is rather negative. ABEO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ABEO has reported negative net income.
In the past year ABEO has reported a negative cash flow from operations.
ABEO had negative earnings in each of the past 5 years.
In the past 5 years ABEO always reported negative operating cash flow.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ABEO has a better Return On Assets (35.63%) than 98.49% of its industry peers.
ABEO has a better Return On Equity (48.09%) than 98.49% of its industry peers.
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

With an excellent Profit Margin value of 20587.50%, ABEO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for ABEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 20587.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABEO has been increased compared to 1 year ago.
The number of shares outstanding for ABEO has been increased compared to 5 years ago.
The debt/assets ratio for ABEO is higher compared to a year ago.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ABEO has an Altman-Z score of -1.61. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
ABEO's Altman-Z score of -1.61 is in line compared to the rest of the industry. ABEO outperforms 51.89% of its industry peers.
ABEO has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
ABEO has a Debt to Equity ratio of 0.06. This is in the lower half of the industry: ABEO underperforms 61.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -1.61
ROIC/WACCN/A
WACC8.79%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ABEO has a Current Ratio of 9.74. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
ABEO has a better Current ratio (9.74) than 79.81% of its industry peers.
A Quick Ratio of 9.53 indicates that ABEO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.53, ABEO is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 9.53
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.38% over the past year.
The Revenue for ABEO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 30.52% on average over the next years. This is a very strong growth
Based on estimates for the next years, ABEO will show a very strong growth in Revenue. The Revenue will grow by 419.83% on average per year.
EPS Next Y172.22%
EPS Next 2Y40.35%
EPS Next 3Y37.32%
EPS Next 5Y30.52%
Revenue Next Year6533.33%
Revenue Next 2Y3248.54%
Revenue Next 3Y1169.2%
Revenue Next 5Y419.83%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ABEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABEO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

ABEO's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.35%
EPS Next 3Y37.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABEO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (12/24/2025, 8:12:06 PM)

After market: 5.41 0 (0%)

5.41

+0.11 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners66.06%
Inst Owner Change0.68%
Ins Owners5.21%
Ins Owner Change-5.08%
Market Cap293.17M
Revenue(TTM)400.00K
Net Income(TTM)82.35M
Analysts86.67
Price Target20.62 (281.15%)
Short Float %28.43%
Short Ratio7.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.03%
Min EPS beat(2)-36.14%
Max EPS beat(2)66.19%
EPS beat(4)3
Avg EPS beat(4)31.61%
Min EPS beat(4)-36.14%
Max EPS beat(4)66.19%
EPS beat(8)4
Avg EPS beat(8)5.48%
EPS beat(12)7
Avg EPS beat(12)27.55%
EPS beat(16)9
Avg EPS beat(16)18.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)-4.4%
EPS NQ rev (3m)-269.47%
EPS NY rev (1m)-3.14%
EPS NY rev (3m)1383.33%
Revenue NQ rev (1m)-33.41%
Revenue NQ rev (3m)-71.2%
Revenue NY rev (1m)-75.86%
Revenue NY rev (3m)-75.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 732.92
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB 1.71
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0.01
BVpS3.16
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 20587.5%
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 476.46%
Cap/Sales 1857%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 9.53
Altman-Z -1.61
F-Score6
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)46.91%
Cap/Depr(5y)59.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
EPS Next Y172.22%
EPS Next 2Y40.35%
EPS Next 3Y37.32%
EPS Next 5Y30.52%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year6533.33%
Revenue Next 2Y3248.54%
Revenue Next 3Y1169.2%
Revenue Next 5Y419.83%
EBIT growth 1Y-36.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-95.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABEONA THERAPEUTICS INC / ABEO FAQ

Can you provide the ChartMill fundamental rating for ABEONA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ABEO.


What is the valuation status for ABEO stock?

ChartMill assigns a valuation rating of 1 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.


Can you provide the profitability details for ABEONA THERAPEUTICS INC?

ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 2 / 10.